Pipeline

About RR&D

 

Our research experience

 

Our innovation

 

Our pipeline

 

Therapeutic areas

Pipeline R&D

Pain & Inflammation Disorders
Nervous System Diseases & Disorders
Non-pharma
Other
Benzydamine new
formulations
Ibuprofen new
formulations
Paracetamol new
formulations
New Delivery Platforms Trazodone
gabapentin
Ibuprofen + paracet
new formulations
Lurasidone
Kv7 Trazodone pediatry Lithium Sulphate
GSK-3beta Trazodone non oral Lurasidone pediatry * Trazodone new
formula/indications
Paracetamol PDA Benzydamine
econazole §
Dalbavancin
Prulifloxacin CBP
Cosmetics, Nutraceutics, Disinfectants
DISCOVERY PRECLINICAL
DEVELOPMENT
PHASE I PHASE II PHASE III PHASE IV
Life cycle Management

* Ready for Phase II
§ Pre-registration

Contact us

We are looking for innovative solutions in healthcare from the early development phase.

If you have an idea or a new project starting from the early development phase and you desire to discuss for potential partnership opportunities, or if you are looking for a partner to accomplish specific development steps, please contact networking@angelini.it

Angelini S.p.a.
Viale Amelia 70, 00181 Roma
P.IVA 01258691003 e C.F. Numero di iscrizione registro imprese: 03907010585
Ufficio del registro delle imprese: Roma
Capitale: € 165.000.000 I.V.

© Angelini S.p.a. - Tutti i diritti riservati